Polhemus, David J.
Trivedi, Rishi K.
Sharp, Thomas E.
Li, Zhen
Goodchild, Traci T.
Scarborough, Amy
de Couto, Geoffrey
Marbán, Eduardo
Lefer, David J.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (1R01 HL092141, 1R01 HL093579, 1U24 HL 094373, 1P20 HL113452, R01 HL133835)
American Heart Association (18CDA34110445)
Article History
Received: 26 November 2018
Revised: 20 December 2018
Accepted: 9 January 2019
First Online: 17 January 2019
Compliance with ethical standards
:
: E.M. owns founder’s equity in Capricor, Inc. GdC receives consulting fees from Capricor. D.J.P. and D.J.L have a pending patent on the use of RDN and cell therapy to treat cardiovascular diseases. R.K.T., T.E.S., A.S., and T.T.G. have nothing to disclose.